NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced a new partnership with ŌURA, maker of the world’s leading smart ring, further empowering women to better understand and take action on their health through comprehensive data and personalized insights. By incorporating wearable data and insights from ŌURA into the care team decision-support process—from preconception to menopause—Progyny is engaging membe ...

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits during the COVID-19 pandemic [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may have until July 11, 2025, to request to lead the case [2]. Group 2: Background on Medicaid Management - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused the review of Medicaid eligibility during COVID-19, which resumed in 2023, leading to increased scrutiny of Medicaid members [3]. Group 3: Financial Implications - Elevance claimed to be monitoring cost trends related to the Medicaid redetermination process and believed their negotiated rates were adequate [4]. - However, the redetermination process resulted in a significant increase in the acuity and utilization of Medicaid members, which was not reflected in Elevance's financial guidance for 2024 [5]. Group 4: Stock Performance - Following Elevance's announcement on July 17, 2024, regarding increased Medicaid utilization, the stock price fell by $32.21, or nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, leading to a further decline in stock price by $52.61, or nearly 11%, from $496.96 to $444.35 per share [7].

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action. Investors have until August 25, 2025, to ask th ...

GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance.The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link posted on Ela ...

Backed by $1 million in funding from the CVS Health Foundation, the pilot initiative offers free, virtual health screenings to support aging with confidence, care, and convenienceHealth checks include assessments for heart health, memory, cognitive function, and mental healthNo travel required — all appointments are virtual and confidentialCommunity Health Workers provide personalized follow-up support and connect patients to local resourcesThe program is now available in New York City, with plans to expand ...

PHILADELPHIA, July 10, 2025 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating National HealthCare Corporation (NYSE: NHC) ("NHC") on behalf of the company's long-term investors. Since November 2024, shares of NHC's common stock have declined in value from a trading price of over $135.00 per share to a current trading price of below $110.00 per share, a decline of nearly 20% in value. The investigation seeks to determine whether NHC and/or the company's officers and directors violated the se ...

SOMERSET, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO) (“CareCloud” or the “Company”), a leader in AI-powered healthcare technology and revenue cycle management solutions, today announced that its common stock rose approximately 70% during the second quarter of 2025, making it among the top gainers in the Russell Microcap® Index for the period. The Company was officially added to the Russell Microcap Index effective June 30, 2025, following the annual reconstitution of the R ...

Financial Performance & Guidance - Omnicell预计2020财年产品预订额约为10亿美元[7] - Omnicell预计2020财年总收入为8.9亿至8.92亿美元[7] - Omnicell预计2020财年Non-GAAP EBITDA为1.57亿至1.59亿美元[7] - Omnicell预计2020财年Non-GAAP每股收益为2.46至2.51美元[7] - Omnicell预计2021财年总收入为10.85亿至11.05亿美元[7] - Omnicell预计2021财年Non-GAAP EBITDA为2.28亿至2.4亿美元[7] - Omnicell预计2021财年Non-GAAP每股收益为3.38至3.58美元[7] Growth & Market Position - Omnicell在医疗保健数字化转型中占据领先地位，潜在市场规模超过700亿美元[7, 10] - Omnicell 目标是2021-2025年收入复合年增长率为14-15%（有机增长11-12%，无机增长3%）[7, 10] - Omnicell 目标是从2021-2025年Non-GAAP EBITDA利润率提高约400个基点[7, 10] - Omnicell 目标是SaaS、订阅软件和技术支持服务在2020-2025年的收入复合年增长率约为50%[7, 10]

DALLAS, July 10, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its second quarter 2025 financial results and third quarter 2025 outlook on Thursday, August 7, 2025, at 5:00 p.m. Eastern Time. On the same day, the Company also expects to issue an earnings news release after market close at approximately 4:15 p.m. Eastern Time. A live webcast of the call can be accessed through this webcast link, which also will be available on AMN Healthcare’s ...

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Reckitt Benckiser Group plc (“Reckitt”) (LSE: RKT; OTCQX: RBGLY, RBGPF), the company behind some of the world's best-loved consumer health and hygiene brands, has qualified to trade on the OTCQX® Best Market. Reckitt upgraded to OTCQX from the Pink® market. Reckitt begins trading today on OTCQX under the symbols “RBGLY” and “RBG ...